Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Enfortumab (DHJ41001)

Host species:Human
Isotype:IgG1-kappa
Applications:Research Grade Biosimilar
Expression system:Mammalian Cells
Overview

Catalog No.

DHJ41001

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Human

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

LNIR, NECTIN4, PRR4 receptor-related protein 4, Nectin cell adhesion molecule 4, Ig superfamily receptor LNIR, Nectin-4, PVRL4

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q96NY8

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

AGS-22CE, AGS-22M, AGS-22M6E, unconjugated : AGS-22C3 or AGSM6, CAS: 1346452-25-2

Clone ID

Enfortumab

Data Image
  • SDS-PAGE
    SDS PAGE for Enfortumab
  • Bioactivity
    Detects NECTIN4/PVRL4 in indirect ELISAs.
  • SEC-HPLC
    The purity of this product is >95% as determined by SEC-HPLC.
References

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy, PMID: 31356140

Enfortumab vedotin to treat urothelial carcinoma, PMID: 32406880

Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models, PMID: 27013195

Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma, PMID: 31823332

Enfortumab Vedotin in urothelial cancer, PMID: 33447264

Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma, PMID: 32945172

EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma, PMID: 32031899

Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma, PMID: 31526130

A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma, PMID: 31444589

FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma, PMID: 32962979

Antibodies to watch in 2020, PMID: 31847708

Enfortumab vedotin shows promise in solid tumours, PMID: 32066546

Enfortumab Vedotin Checks Urothelial Cancer, PMID: 31519705

Enfortumab vedotin - next game-changer in urothelial cancer, PMID: 33325754

Flexural Exanthema From Enfortumab Vedotin, PMID: 32542157

The biology and rationale of targeting nectin-4 in urothelial carcinoma, PMID: 33239713

Management of metastatic bladder cancer, PMID: 31030123

Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma, PMID: 33301805

Enfortumab Vedotin, PMID: 33630480

Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin, PMID: 32982431

Antibodies to watch in 2019, PMID: 30516432

The emerging role of antibody-drug conjugates in urothelial carcinoma, PMID: 32552213

Targeting Nectin-4 in Bladder Cancer, PMID: 28634245

A rare presentation of enfortumab vedotin-induced toxic epidermal necrolysis, PMID: 33319007

Antibody-Drug Conjugates in Urothelial Carcinomas, PMID: 32008109

Enfortumab vedotin is safe and effective, PMID: 34031573

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma, PMID: 33577729

Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma, PMID: 30865407

Enfortumab vedotin for cisplatin-ineligible urothelial cancer, PMID: 33991513

Enfortumab Vedotin in Advanced Urothelial Carcinoma, PMID: 34192440

Enfortumab Vedotin in Advanced Urothelial Carcinoma. Reply, PMID: 34192441

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial, PMID: 33991512

Benefit with enfortumab vedotin confirmed, PMID: 33649567

Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date, PMID: 33603337

Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma, PMID: 32751328

Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin, PMID: 33604101

Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?, PMID: 33019653

Re: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma, PMID: 33895011

Severe eczematoid and lichenoid eruption with full-thickness epidermal necrosis developing from metastatic urothelial cancer treated with enfortumab vedotin, PMID: 32860247

Enfortumab Vedotin: Nursing Perspectives on the Management of Adverse Events in Patients With Locally Advanced or Metastatic Urothelial Carcinoma, PMID: 33739346

New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far?, PMID: 34148797

Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction, PMID: 33747934

Current Systemic Treatment Options in Metastatic Urothelial Carcinoma after Progression on Checkpoint Inhibition Therapy-A Systemic Review Combined with Single-Group Meta-Analysis of Three Studies Testing Enfortumab Vedotin, PMID: 34206980

Benefit of nectin-4 targeting with enfortumab vedotin confirmed, PMID: 33692500

Cutaneous reactions with enfortumab vedotin: A case series and review of the literature, PMID: 34235241

Antibody-Drug Conjugates in Bladder Cancer, PMID: 30112436

Emerging biomarkers in urothelial carcinoma: Challenges and opportunities, PMID: 32920502

Antibody-drug conjugates for the treatment of urothelial carcinoma, PMID: 32589063

Updates in the management and future landscape of urothelial carcinoma, PMID: 33143526

The Evolution of Antibody-Drug Conjugates: A Positive Inflexion Point, PMID: 32223669

Datasheet

Document Download

Research Grade Enfortumab.pdf

 

$ 328
Product specifications
100 μg 328 1 mg 1314

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Enfortumab [DHJ41001]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2024 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only